fenofibrate has been researched along with Body Weight in 81 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate." | 9.17 | Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment. ( Drapalova, J; Haluzik, M; Haluzikova, D; Kavalkova, P; Lacinova, Z; Matoulek, M; Mraz, M; Novak, D; Roubicek, T; Touskova, V; Trachta, P; Urbanova, M, 2013) |
| "To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia." | 9.13 | Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. ( Elisaf, M; Filippatos, TD; Florentin, M; Kostara, C; Liberopoulos, EN; Mikhailidis, DP; Tselepis, A, 2008) |
| "Fenofibrate (FF) is commonly used clinically as a lipid-lowering drug, but whether it participates in endoplasmic reticulum (ER) stress and decreases inflammation in skeletal muscle is still unknown." | 7.83 | Fenofibrate improves high-fat diet-induced and palmitate-induced endoplasmic reticulum stress and inflammation in skeletal muscle. ( Bao, YY; Chen, GJ; Chen, L; Dai, F; Jiang, T; Lu, YX; Zhang, Q, 2016) |
| " Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats." | 7.80 | Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. ( Elshazly, SM; Mahmoud, AA, 2014) |
| " Fenofibrate, a lipid-modifying agent that acts as a PPARalpha agonist, may prevent adipocyte hypertrophy and insulin resistance by increasing intracellular lipolysis from adipose tissue." | 7.75 | Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. ( Jeong, S; Yoon, M, 2009) |
| " The aim of this study was to investigate the effect of two different treatment periods of fenofibrate (CAS 49562-28-9) on serum, heart and liver sialic acid levels in experimental hypercholesterolemia." | 7.74 | Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia. ( Emekli, N; Oztürk, LK; Yarat, A, 2007) |
| "We investigated whether fenofibrate improves lipid metabolism and obesity in female ovariectomized (OVX) or sham-operated (SO) low density lipoprotein receptor-null (LDLR-null) mice." | 7.72 | Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. ( Han, M; Jeong, S; Kang, JH; Kim, EY; Kim, M; Lee, H; Oh, GT; Yoon, M, 2003) |
| " To determine whether fenofibrate reduces body weight gain and adiposity in female sham-operated (Sham) and ovariectomized (OVX) C57BL/6J mice, the effects of fenofibrate on not only body weight, white adipose tissue (WAT) mass, and food intake, but also the expression of both leptin and PPARalpha target genes were measured." | 7.72 | Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. ( Choi, JH; Han, M; Jeong, S; Kim, BH; Kim, J; Kim, M; Lee, H; Nam, KH; Nicol, CJ; Oh, GT; Yoon, M, 2004) |
| "Our previous study demonstrated that fenofibrate improves both lipid metabolism and obesity, in part through hepatic peroxisome proliferator-activated receptor alpha (PPARalpha) activation, in female ovariectomized, but not in sham-operated, low-density lipoprotein receptor-null (LDLR-null) mice." | 7.72 | Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. ( Ahn, J; Han, M; Jeong, S; Kim, M; Kim, TW; Lee, H; Nam, KH; Oh, GT; Shin, C; Song, YH; Yoon, M, 2004) |
| "To determine whether the PPARalpha agonist fenofibrate regulates obesity and lipid metabolism with sexual dimorphism, we examined the effects of fenofibrate on body weight, white adipose tissue (WAT) mass, circulating lipids, and the expression of PPARalpha target genes in both sexes of high fat diet-fed C57BL/6J mice." | 7.71 | Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. ( Han, M; Jeong, S; Kim, JJ; Lee, H; Nicol, CJ; Oh, GT; Ryu, C; Seo, YJ; Yoon, M, 2002) |
| " We compared the pharmacological profile of a PPARalpha activator, fenofibrate, and a PPARgamma activator, rosiglitazone, on serum parameters, target gene expression, and body weight gain in (fa/fa) fatty Zucker rats and db/db mice as well as their association in db/db mice." | 7.70 | Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. ( Chaput, E; Edgar, AD; Saladin, R; Silvestre, M, 2000) |
| "The results indicate that, in experimental arthritis, fenofibrate decreases skeletal muscle atrophy through inhibition of the ubiquitin-proteasome system and myostatin." | 5.37 | Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. ( Castillero, E; Fernández-Galaz, C; Granado, M; López-Calderón, A; López-Menduiña, M; Martín, AI; Nieto-Bona, MP; Villanúa, MA, 2011) |
| " The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate." | 5.17 | Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment. ( Drapalova, J; Haluzik, M; Haluzikova, D; Kavalkova, P; Lacinova, Z; Matoulek, M; Mraz, M; Novak, D; Roubicek, T; Touskova, V; Trachta, P; Urbanova, M, 2013) |
| "During the 8-week double-blind phase in subjects receiving fenofibrate, the addition of P-OM3 (versus placebo) did not significantly change median (minimum, maximum) body weight (P-OM3 = 0 [-4." | 5.14 | The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. ( Bays, HE; Doyle, RT; Maki, KC; Stein, E, 2009) |
| "To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia." | 5.13 | Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. ( Elisaf, M; Filippatos, TD; Florentin, M; Kostara, C; Liberopoulos, EN; Mikhailidis, DP; Tselepis, A, 2008) |
| "Letrozole-treated rats showed successful induction of PCOS, confirmed by histopathology and significantly increased body weight, testosterone, insulin, AMH, and MDA, and decreased SOD." | 4.12 | Fenofibrate ameliorates letrozole-induced polycystic ovary in rats via modulation of PPARα and TNFα/CD95 pathway. ( El-Hussieny, M; Morsy, MA; Nair, AB; Refaie, MMM; Venugopala, KN; Zenhom, NM, 2022) |
| "Fenofibrate (FF) is commonly used clinically as a lipid-lowering drug, but whether it participates in endoplasmic reticulum (ER) stress and decreases inflammation in skeletal muscle is still unknown." | 3.83 | Fenofibrate improves high-fat diet-induced and palmitate-induced endoplasmic reticulum stress and inflammation in skeletal muscle. ( Bao, YY; Chen, GJ; Chen, L; Dai, F; Jiang, T; Lu, YX; Zhang, Q, 2016) |
| " Fenofibrate treated mice gained less body weight (BW) and had lower serum amyloid A (SAA) levels, but higher Interleukin (IL)-1α and MIP1α than other mice." | 3.80 | Statins and fibrates do not affect development of spontaneous cartilage damage in STR/Ort mice. ( Bastiaansen-Jenniskens, YM; Bierma-Zeinstra, SM; Botter, SM; Clockaerts, S; Gierman, LM; Kloppenburg, M; van Osch, GJ; Verhaar, JA; Wei, W; Weinans, H; Zuurmond, AM, 2014) |
| " Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats." | 3.80 | Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats. ( Elshazly, SM; Mahmoud, AA, 2014) |
| " We followed the spontaneous evolution of liver steatosis and tested the therapeutic usefulness of metformin and fenofibrate in a model of steatosis, the Zucker diabetic fatty (ZDF) rat." | 3.75 | Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. ( Abdallah, P; Basset, A; Beylot, M; del Carmine, P; Forcheron, F; Haffar, G, 2009) |
| " Here, in an animal model of obesity and insulin resistance, the metabolic response to cevoglitazar, a dual PPARalpha/gamma, was characterized using a combination of in vivo and ex vivo magnetic resonance methodologies and compared to treatment effects of fenofibrate, a PPARalpha agonist, and pioglitazone, a PPARgamma agonist." | 3.75 | Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. ( Boettcher, BR; Gao, J; Gounarides, JS; Laurent, D, 2009) |
| " Fenofibrate, a lipid-modifying agent that acts as a PPARalpha agonist, may prevent adipocyte hypertrophy and insulin resistance by increasing intracellular lipolysis from adipose tissue." | 3.75 | Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. ( Jeong, S; Yoon, M, 2009) |
| "The PPAR-alpha agonists fenofibrate and n-3 PUFA could efficiently activate AMPK-alpha1 mRNA expression in liver and skeletal muscle to exert body weight reduction and hypoglycaemic effect, respectively." | 3.75 | Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats. ( El-Razek, SM; Hashem, RM; Motawi, TM; Rashed, LA, 2009) |
| " After they were treated with combinations of high fat, fenofibrate (FF), or 17beta-estradiol (E) for 13 weeks, variables and determinants of obesity and lipid metabolism were measured using in vivo and in vitro approaches." | 3.74 | Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen. ( Jeong, S; Yoon, M, 2007) |
| " The aim of this study was to investigate the effect of two different treatment periods of fenofibrate (CAS 49562-28-9) on serum, heart and liver sialic acid levels in experimental hypercholesterolemia." | 3.74 | Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia. ( Emekli, N; Oztürk, LK; Yarat, A, 2007) |
| " Despite similarities in total body weight in all groups, compared with control fed groups, chocolate-supplemented animals had significantly higher plasma triacylglyceride and non-esterified fatty acids and leptin (for all, P<0." | 3.73 | The effects of fenofibrate on metabolic and vascular changes induced by chocolate-supplemented diet in the rat. ( Fatani, S; Naderali, EK, 2005) |
| "We investigated whether fenofibrate improves lipid metabolism and obesity in female ovariectomized (OVX) or sham-operated (SO) low density lipoprotein receptor-null (LDLR-null) mice." | 3.72 | Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. ( Han, M; Jeong, S; Kang, JH; Kim, EY; Kim, M; Lee, H; Oh, GT; Yoon, M, 2003) |
| "Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent." | 3.72 | Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. ( Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC, 2003) |
| "The PPAR-gamma ligand rosiglitazone, but not the PPAR-alpha ligand fenofibrate, decreases intimal hyperplasia following balloon injury in both fatty and lean Zucker rats." | 3.72 | Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. ( Desouza, CV; Diez, J; Dunne, B; Fonseca, VA; Matta, AS; McNamara, DB; Murthy, SN, 2003) |
| "Our previous study demonstrated that fenofibrate improves both lipid metabolism and obesity, in part through hepatic peroxisome proliferator-activated receptor alpha (PPARalpha) activation, in female ovariectomized, but not in sham-operated, low-density lipoprotein receptor-null (LDLR-null) mice." | 3.72 | Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. ( Ahn, J; Han, M; Jeong, S; Kim, M; Kim, TW; Lee, H; Nam, KH; Oh, GT; Shin, C; Song, YH; Yoon, M, 2004) |
| " Fenofibrate treatment did not change serum lipid levels during the feeding period, but decreased high cholesterol diet-induced increases in body weight by 19% and serum TNF-alpha concentration by 44." | 3.72 | Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits. ( Wu, J; Zhao, SP, 2004) |
| " To determine whether fenofibrate reduces body weight gain and adiposity in female sham-operated (Sham) and ovariectomized (OVX) C57BL/6J mice, the effects of fenofibrate on not only body weight, white adipose tissue (WAT) mass, and food intake, but also the expression of both leptin and PPARalpha target genes were measured." | 3.72 | Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. ( Choi, JH; Han, M; Jeong, S; Kim, BH; Kim, J; Kim, M; Lee, H; Nam, KH; Nicol, CJ; Oh, GT; Yoon, M, 2004) |
| "To determine whether the PPARalpha agonist fenofibrate regulates obesity and lipid metabolism with sexual dimorphism, we examined the effects of fenofibrate on body weight, white adipose tissue (WAT) mass, circulating lipids, and the expression of PPARalpha target genes in both sexes of high fat diet-fed C57BL/6J mice." | 3.71 | Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. ( Han, M; Jeong, S; Kim, JJ; Lee, H; Nicol, CJ; Oh, GT; Ryu, C; Seo, YJ; Yoon, M, 2002) |
| " We compared the pharmacological profile of a PPARalpha activator, fenofibrate, and a PPARgamma activator, rosiglitazone, on serum parameters, target gene expression, and body weight gain in (fa/fa) fatty Zucker rats and db/db mice as well as their association in db/db mice." | 3.70 | Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. ( Chaput, E; Edgar, AD; Saladin, R; Silvestre, M, 2000) |
| "In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels." | 2.73 | Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. ( Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M, 2007) |
| "When fenofibrate was administered to the fatty liver model created via GAN administration and liver steatosis was assessed, a reduction in liver fat deposition was observed, and this model was shown to be useful in drug evaluations involving fatty liver." | 1.62 | Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose. ( Fujisawa, K; Kondo, K; Matsumoto, T; Nishimura, Y; Okubo, S; Sakaida, I; Takami, T; Yamada, Y; Yamamoto, N, 2021) |
| "In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance." | 1.48 | PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling. ( Dai, M; Gonzalez, FJ; Hua, H; Huang, J; Lin, H; Liu, A; Liu, L; Wang, F; Xi, Y; Xu, G; Yang, J; Zhao, T, 2018) |
| "Moreover, this work implies the enhanced liver fibrosis (ELF) panel diagnostic performance in diagnosis of any and moderate degree of fibrosis in rats with NAFLD." | 1.46 | Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats. ( Abd-Elaziz, LF; Boctor, SS; El-Kharashi, OA; Hamed, AM, 2017) |
| "Fenofibrate was given to db/db mice in combination with anti-flt-1 hexamer and anti-flk-1 heptamer (VEGFR inhibition) for 12 weeks." | 1.40 | Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. ( Chang, YS; Cho, YR; Hong, BY; Kim, HW; Kim, MY; Kim, TW; Kim, YS; Lim, JH; Park, CW, 2014) |
| "Treatment with fenofibrate exerted a better effect on clinical scoring." | 1.40 | Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis. ( Jouzeau, JY; Koufany, M; Moulin, D, 2014) |
| "Metformin has been reported to increase the expression of the glucagon-like peptide-1 (GLP-1) receptor in pancreatic beta cells in a peroxisome proliferator-activated receptor (PPAR)-α-dependent manner." | 1.39 | Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats. ( Cho, YM; Kang, GH; Oh, TJ; Park, KS; Shin, JY, 2013) |
| " Oral dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i." | 1.39 | Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. ( Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V, 2013) |
| "The development of diabetic nephropathy was assessed biochemically and histologically." | 1.39 | Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. ( Balakumar, P; Kadian, S; Mahadevan, N, 2013) |
| "Fenofibrate treatment significantly attenuated oxidative damage, cytokines and improved mitochondrial complexes enzyme activity in brain." | 1.38 | Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms. ( Bhateja, DK; Dhull, DK; Gill, A; Padi, SS; Reddy, BV; Sharma, S; Sidhu, A, 2012) |
| "Prevention of left ventricular hypertrophy remains a challenge in the prevention of hypertension-induced adverse cardiac remodeling." | 1.37 | Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart. ( Nair, RR; Purushothaman, S; Sathik, MM, 2011) |
| "The results indicate that, in experimental arthritis, fenofibrate decreases skeletal muscle atrophy through inhibition of the ubiquitin-proteasome system and myostatin." | 1.37 | Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. ( Castillero, E; Fernández-Galaz, C; Granado, M; López-Calderón, A; López-Menduiña, M; Martín, AI; Nieto-Bona, MP; Villanúa, MA, 2011) |
| "Fenofibrate (FF) has previously been shown to induce hepatocellular neoplasia in a conventional mouse bioassay (NDA 1993), but there has been no report to examine the carcinogenic susceptibility of rasH2 mice to this chemical." | 1.35 | Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice. ( Dewa, Y; Jin, M; Kawai, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saegusa, Y; Shibutani, M; Taniai, E, 2008) |
| "Fenofibrate treatment also prevented the diet-induced decrease in cardiac function and improved post-ischemic functional recovery." | 1.35 | Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. ( Aasum, E; Berge, RK; Gudbrandsen, OA; How, OJ; Khalid, AM; Larsen, TS, 2008) |
| "Fenofibrate is a drug that has been suggested to inhibit weight gain by increasing the catabolism of fatty acid in the hepatic mitochondria." | 1.34 | The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats. ( Choi, SS; Hong, SH; Kim, DK; Lee, HJ; Lee, KI; Park, MK; Yoo, YH, 2007) |
| "Fenofibrate treatment dramatically reduced fasting blood glucose (P<0." | 1.33 | PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. ( Breyer, M; Cha, DR; Chen, L; Davis, L; Fan, X; Guan, Y; Hwang, MT; Park, CW; Striker, G; Su, D; Wu, J; Zhang, X; Zhang, Y; Zheng, F, 2006) |
| "Body weights were recorded weekly, and plasma lipid profiles were determined at 4-week intervals." | 1.33 | Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. ( Bahadori, B; Declercq, V; Khademi, H; Moghadasian, MH; Moshtaghi-Kashanian, GR; Yeganeh, B, 2005) |
| "Fenofibrate increase mitochondrial fatty acid beta-oxidation in liver but not in skeletal muscle and lower the plasma levels of triglyceride and free fatty acid." | 1.31 | Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. ( An, YJ; Choi, SS; Garber, AJ; Hong, SH; Hwang, TH; Kang, DY; Kim, DK; Kim, MC; Lee, HJ; Park, MK; Seo, SY, 2002) |
| "Fenofibrate is a member of the fibrate class of hypolipidemic agents used clinically to treat hypertriglyceridemia and mixed hyperlipidemia." | 1.31 | Effects of fenofibrate on lipid parameters in obese rhesus monkeys. ( Bodkin, NL; Brown, HR; Brown, PJ; Hansen, BC; Kliewer, SA; Lehmann, JM; Lewis, MC; Ott, RJ; Plunket, KD; Tong, WQ; Way, JM; Wilkison, WO; Winegar, DA, 2001) |
| "Eleven patients with hyperlipoproteinemia (HLP) type II A, were treated for 3 months with a new compound, a phenoxy-isobuturic acid derivative, procetofen, at a dosage of 100 mg t." | 1.26 | Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. ( Gustafson, A; Micheli, H; Pometta, D, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (8.64) | 18.7374 |
| 1990's | 3 (3.70) | 18.2507 |
| 2000's | 44 (54.32) | 29.6817 |
| 2010's | 25 (30.86) | 24.3611 |
| 2020's | 2 (2.47) | 2.80 |
| Authors | Studies |
|---|---|
| Ashton, MJ | 1 |
| Ashford, A | 1 |
| Loveless, AH | 1 |
| Riddell, D | 1 |
| Salmon, J | 1 |
| Stevenson, GV | 1 |
| Papi Reddy, K | 1 |
| Singh, AB | 1 |
| Puri, A | 1 |
| Srivastava, AK | 1 |
| Narender, T | 1 |
| Mokale, SN | 1 |
| Sanap, PT | 1 |
| Shinde, DB | 1 |
| Porcelli, L | 1 |
| Gilardi, F | 1 |
| Laghezza, A | 1 |
| Piemontese, L | 1 |
| Mitro, N | 1 |
| Azzariti, A | 1 |
| Altieri, F | 1 |
| Cervoni, L | 1 |
| Fracchiolla, G | 1 |
| Giudici, M | 1 |
| Guerrini, U | 1 |
| Lavecchia, A | 1 |
| Montanari, R | 1 |
| Di Giovanni, C | 1 |
| Paradiso, A | 1 |
| Pochetti, G | 1 |
| Simone, GM | 1 |
| Tortorella, P | 1 |
| Crestani, M | 1 |
| Loiodice, F | 1 |
| Fujisawa, K | 1 |
| Takami, T | 1 |
| Okubo, S | 1 |
| Nishimura, Y | 1 |
| Yamada, Y | 1 |
| Kondo, K | 1 |
| Matsumoto, T | 1 |
| Yamamoto, N | 1 |
| Sakaida, I | 1 |
| Morsy, MA | 1 |
| El-Hussieny, M | 1 |
| Zenhom, NM | 1 |
| Nair, AB | 1 |
| Venugopala, KN | 1 |
| Refaie, MMM | 1 |
| Hua, H | 1 |
| Yang, J | 1 |
| Lin, H | 1 |
| Xi, Y | 1 |
| Dai, M | 1 |
| Xu, G | 1 |
| Wang, F | 1 |
| Liu, L | 1 |
| Zhao, T | 1 |
| Huang, J | 1 |
| Gonzalez, FJ | 1 |
| Liu, A | 1 |
| Oh, TJ | 1 |
| Shin, JY | 1 |
| Kang, GH | 1 |
| Park, KS | 1 |
| Cho, YM | 1 |
| Grover, S | 1 |
| Kumar, P | 1 |
| Singh, K | 1 |
| Vikram, V | 1 |
| Budhiraja, RD | 1 |
| Kavalkova, P | 1 |
| Touskova, V | 1 |
| Roubicek, T | 1 |
| Trachta, P | 1 |
| Urbanova, M | 1 |
| Drapalova, J | 1 |
| Haluzikova, D | 1 |
| Mraz, M | 1 |
| Novak, D | 1 |
| Matoulek, M | 1 |
| Lacinova, Z | 1 |
| Haluzik, M | 1 |
| Wei, W | 1 |
| Clockaerts, S | 1 |
| Bastiaansen-Jenniskens, YM | 1 |
| Gierman, LM | 1 |
| Botter, SM | 1 |
| Bierma-Zeinstra, SM | 1 |
| Weinans, H | 1 |
| Verhaar, JA | 1 |
| Kloppenburg, M | 1 |
| Zuurmond, AM | 1 |
| van Osch, GJ | 1 |
| Cho, YR | 1 |
| Lim, JH | 1 |
| Kim, MY | 1 |
| Kim, TW | 2 |
| Hong, BY | 1 |
| Kim, YS | 1 |
| Chang, YS | 1 |
| Kim, HW | 1 |
| Park, CW | 2 |
| Greene-Schloesser, D | 1 |
| Payne, V | 1 |
| Peiffer, AM | 1 |
| Hsu, FC | 1 |
| Riddle, DR | 1 |
| Zhao, W | 1 |
| Chan, MD | 1 |
| Metheny-Barlow, L | 1 |
| Robbins, ME | 1 |
| Koufany, M | 1 |
| Jouzeau, JY | 1 |
| Moulin, D | 1 |
| Mahmoud, AA | 1 |
| Elshazly, SM | 1 |
| Zhou, C | 1 |
| Zhou, J | 1 |
| Han, N | 1 |
| Liu, Z | 1 |
| Xiao, B | 1 |
| Yin, J | 1 |
| Chu, ZS | 1 |
| Yu, ZL | 1 |
| Pan, SY | 1 |
| Jia, ZH | 1 |
| Wang, XY | 1 |
| Zhang, Y | 2 |
| Zhu, PL | 1 |
| Wang, XJ | 1 |
| Ko, KM | 1 |
| Shih, CC | 1 |
| Wu, JB | 1 |
| Jian, JY | 1 |
| Lin, CH | 1 |
| Ho, HY | 1 |
| Abd El-Haleim, EA | 1 |
| Bahgat, AK | 1 |
| Saleh, S | 1 |
| Dai, F | 1 |
| Jiang, T | 1 |
| Bao, YY | 1 |
| Chen, GJ | 1 |
| Chen, L | 2 |
| Zhang, Q | 1 |
| Lu, YX | 1 |
| Hamed, AM | 1 |
| El-Kharashi, OA | 1 |
| Boctor, SS | 1 |
| Abd-Elaziz, LF | 1 |
| Metais, C | 1 |
| Forcheron, F | 3 |
| Abdallah, P | 2 |
| Basset, A | 3 |
| Del Carmine, P | 3 |
| Bricca, G | 1 |
| Beylot, M | 3 |
| Nishimura, J | 3 |
| Dewa, Y | 3 |
| Okamura, T | 2 |
| Jin, M | 3 |
| Saegusa, Y | 3 |
| Kawai, M | 2 |
| Umemura, T | 2 |
| Shibutani, M | 2 |
| Mitsumori, K | 3 |
| Florentin, M | 1 |
| Liberopoulos, EN | 1 |
| Filippatos, TD | 1 |
| Kostara, C | 1 |
| Tselepis, A | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, M | 1 |
| Matsumoto, S | 1 |
| Taniai, E | 1 |
| Porta, N | 1 |
| Vallée, L | 1 |
| Lecointe, C | 1 |
| Bouchaert, E | 1 |
| Staels, B | 1 |
| Bordet, R | 1 |
| Auvin, S | 1 |
| Laurent, D | 1 |
| Gounarides, JS | 1 |
| Gao, J | 1 |
| Boettcher, BR | 1 |
| Zhao, Z | 1 |
| Lee, YJ | 1 |
| Kim, SK | 1 |
| Kim, HJ | 1 |
| Shim, WS | 1 |
| Ahn, CW | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Ma, ZA | 1 |
| Jeong, S | 6 |
| Yoon, M | 6 |
| Haffar, G | 1 |
| Motawi, TM | 1 |
| Hashem, RM | 1 |
| Rashed, LA | 1 |
| El-Razek, SM | 1 |
| Knapik-Czajka, M | 1 |
| Gozdzialska, A | 1 |
| Jaskiewicz, J | 1 |
| Bays, HE | 1 |
| Maki, KC | 1 |
| Doyle, RT | 1 |
| Stein, E | 1 |
| Castillero, E | 1 |
| Nieto-Bona, MP | 1 |
| Fernández-Galaz, C | 1 |
| Martín, AI | 1 |
| López-Menduiña, M | 1 |
| Granado, M | 1 |
| Villanúa, MA | 1 |
| López-Calderón, A | 1 |
| Chen, W | 1 |
| Zhang, LH | 1 |
| Liu, HY | 1 |
| Zhou, XB | 1 |
| Wang, LL | 1 |
| del Campo, L | 1 |
| Blanco-Rivero, J | 1 |
| Balfagon, G | 1 |
| Purushothaman, S | 1 |
| Sathik, MM | 1 |
| Nair, RR | 1 |
| Bhateja, DK | 1 |
| Dhull, DK | 1 |
| Gill, A | 1 |
| Sidhu, A | 1 |
| Sharma, S | 1 |
| Reddy, BV | 1 |
| Padi, SS | 1 |
| Pettersen, JC | 1 |
| Pruimboom-Brees, I | 1 |
| Francone, OL | 1 |
| Amacher, DE | 1 |
| Boldt, SE | 1 |
| Kerlin, RL | 1 |
| Ballinger, WE | 1 |
| Sisková, K | 1 |
| Bilka, F | 1 |
| Adameová, A | 1 |
| Balazová, A | 1 |
| Mydla, M | 1 |
| Pauliková, I | 1 |
| Kadian, S | 1 |
| Mahadevan, N | 1 |
| Balakumar, P | 1 |
| Lee, HJ | 2 |
| Choi, SS | 2 |
| Park, MK | 2 |
| An, YJ | 1 |
| Seo, SY | 1 |
| Kim, MC | 1 |
| Hong, SH | 2 |
| Hwang, TH | 1 |
| Kang, DY | 1 |
| Garber, AJ | 1 |
| Kim, DK | 2 |
| Iglarz, M | 2 |
| Touyz, RM | 2 |
| Amiri, F | 2 |
| Lavoie, MF | 1 |
| Diep, QN | 2 |
| Schiffrin, EL | 2 |
| Nicol, CJ | 2 |
| Lee, H | 4 |
| Han, M | 4 |
| Kim, JJ | 1 |
| Seo, YJ | 1 |
| Ryu, C | 1 |
| Oh, GT | 4 |
| Guillou, H | 1 |
| Martin, P | 1 |
| Jan, S | 1 |
| D'Andrea, S | 1 |
| Roulet, A | 1 |
| Catheline, D | 1 |
| Rioux, V | 1 |
| Pineau, T | 1 |
| Legrand, P | 1 |
| Kang, JH | 1 |
| Kim, EY | 1 |
| Kim, M | 4 |
| Viel, EC | 1 |
| Paradis, P | 1 |
| Warren, JM | 1 |
| Simon, VA | 1 |
| Bartolini, G | 1 |
| Erickson, KL | 1 |
| Mackey, BE | 1 |
| Kelley, DS | 1 |
| Tuomilehto, J | 1 |
| Desouza, CV | 1 |
| Murthy, SN | 1 |
| Diez, J | 1 |
| Dunne, B | 1 |
| Matta, AS | 1 |
| Fonseca, VA | 1 |
| McNamara, DB | 1 |
| Cornwell, PD | 1 |
| De Souza, AT | 1 |
| Ulrich, RG | 1 |
| Ahn, J | 1 |
| Song, YH | 1 |
| Shin, C | 1 |
| Nam, KH | 2 |
| Zhao, SP | 1 |
| Wu, J | 2 |
| Kim, J | 1 |
| Kim, BH | 1 |
| Choi, JH | 1 |
| Sebestjen, M | 1 |
| Keber, I | 1 |
| Zegura, B | 1 |
| Simcic, S | 1 |
| Bozic, M | 1 |
| Fressart, MM | 1 |
| Stegnar, M | 1 |
| Yeganeh, B | 2 |
| Moshtaghi-Kashanian, GR | 2 |
| Declercq, V | 2 |
| Moghadasian, MH | 2 |
| Reifel-Miller, A | 1 |
| Otto, K | 1 |
| Hawkins, E | 1 |
| Barr, R | 1 |
| Bensch, WR | 1 |
| Bull, C | 1 |
| Dana, S | 1 |
| Klausing, K | 1 |
| Martin, JA | 1 |
| Rafaeloff-Phail, R | 1 |
| Rafizadeh-Montrose, C | 1 |
| Rhodes, G | 1 |
| Robey, R | 1 |
| Rojo, I | 1 |
| Rungta, D | 1 |
| Snyder, D | 1 |
| Wilbur, K | 1 |
| Zhang, T | 1 |
| Zink, R | 1 |
| Warshawsky, A | 1 |
| Brozinick, JT | 1 |
| Khademi, H | 1 |
| Bahadori, B | 1 |
| Choi, KC | 1 |
| Ryu, OH | 1 |
| Lee, KW | 1 |
| Kim, HY | 1 |
| Seo, JA | 1 |
| Kim, SG | 1 |
| Kim, NH | 1 |
| Choi, DS | 1 |
| Baik, SH | 1 |
| Choi, KM | 1 |
| Naderali, EK | 1 |
| Fatani, S | 1 |
| Zhang, X | 1 |
| Cha, DR | 1 |
| Su, D | 1 |
| Hwang, MT | 1 |
| Fan, X | 1 |
| Davis, L | 1 |
| Striker, G | 1 |
| Zheng, F | 1 |
| Breyer, M | 1 |
| Guan, Y | 1 |
| Serisier, S | 1 |
| Briand, F | 1 |
| Ouguerram, K | 1 |
| Siliart, B | 1 |
| Magot, T | 1 |
| Nguyen, P | 1 |
| Pierno, S | 1 |
| Didonna, MP | 1 |
| Cippone, V | 1 |
| De Luca, A | 1 |
| Pisoni, M | 1 |
| Frigeri, A | 1 |
| Nicchia, GP | 1 |
| Svelto, M | 1 |
| Chiesa, G | 1 |
| Sirtori, C | 1 |
| Scanziani, E | 1 |
| Rizzo, C | 1 |
| De Vito, D | 1 |
| Conte Camerino, D | 1 |
| Yoo, YH | 1 |
| Lee, KI | 1 |
| Otto, C | 1 |
| Otto, B | 1 |
| Frost, RJ | 1 |
| Vogeser, M | 1 |
| Pfeiffer, AF | 1 |
| Spranger, J | 1 |
| Parhofer, KG | 1 |
| Aasum, E | 1 |
| Khalid, AM | 1 |
| Gudbrandsen, OA | 1 |
| How, OJ | 1 |
| Berge, RK | 1 |
| Larsen, TS | 1 |
| Muguruma, M | 1 |
| Oztürk, LK | 1 |
| Yarat, A | 1 |
| Emekli, N | 1 |
| Barnard, SD | 1 |
| Molello, JA | 1 |
| Caldwell, WJ | 1 |
| Lebeau, JE | 1 |
| Bélichard, P | 1 |
| Pruneau, D | 1 |
| Zhiri, A | 1 |
| Arnaiz, SL | 1 |
| Travacio, M | 1 |
| Llesuy, S | 1 |
| Boveris, A | 1 |
| Yamamoto, K | 1 |
| Fukuda, N | 1 |
| Zhang, L | 1 |
| Sakai, T | 1 |
| Chaput, E | 1 |
| Saladin, R | 1 |
| Silvestre, M | 1 |
| Edgar, AD | 1 |
| Winegar, DA | 1 |
| Brown, PJ | 1 |
| Wilkison, WO | 1 |
| Lewis, MC | 1 |
| Ott, RJ | 1 |
| Tong, WQ | 1 |
| Brown, HR | 1 |
| Lehmann, JM | 1 |
| Kliewer, SA | 1 |
| Plunket, KD | 1 |
| Way, JM | 1 |
| Bodkin, NL | 1 |
| Hansen, BC | 1 |
| Micheli, H | 1 |
| Pometta, D | 1 |
| Gustafson, A | 1 |
| Ujházy, E | 1 |
| Onderová, E | 1 |
| Horáková, M | 1 |
| Bencová, E | 1 |
| Durisová, M | 1 |
| Nosál, R | 1 |
| Balonová, T | 1 |
| Zeljenková, D | 1 |
| Fournel, S | 1 |
| Magdalou, J | 1 |
| Pinon, P | 1 |
| Siest, G | 1 |
| Mounié, J | 1 |
| Champion, L | 1 |
| Goudonnet, H | 1 |
| Escousse, A | 1 |
| Truchot, RC | 1 |
| Weisweiler, P | 1 |
| Merk, W | 1 |
| Jacob, B | 1 |
| Schwandt, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Omacor Therapy in Hypertriglyceridemic Subjects Treated With Antara, Followed by an 8-week Extension[NCT00246636] | Phase 4 | 167 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fenofibrate and Body Weight
| Article | Year |
|---|---|
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2003 |
5 trials available for fenofibrate and Body Weight
| Article | Year |
|---|---|
Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment.
Topics: Anthropometry; Body Weight; Calcium-Binding Proteins; Caloric Restriction; Diabetes Mellitus, Type 2 | 2013 |
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.
Topics: Blood Pressure; Body Mass Index; Body Weight; Cardiovascular System; Female; Fenofibrate; Heart; Hum | 2008 |
The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Topics: Adult; Aged; Body Weight; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combinati | 2009 |
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Prote | 2004 |
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus | 2007 |
75 other studies available for fenofibrate and Body Weight
| Article | Year |
|---|---|
Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity.
Topics: Animals; Body Weight; Chemical Phenomena; Chemistry; Cholesterol, Dietary; Eating; Hypolipidemic Age | 1984 |
Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemistry, Pharmaceutical; Cricetinae; Diabetes Mell | 2009 |
Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.
Topics: Acetates; Animals; Body Weight; Female; Hypolipidemic Agents; Lipid Metabolism; Male; Motor Activity | 2010 |
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
Topics: Adipocytes; Animals; Antineoplastic Agents; Benzoxazoles; Body Weight; Calorimetry; Cell Differentia | 2012 |
Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Female; Fenofibrate; Fructose; Gene Ex | 2021 |
Fenofibrate ameliorates letrozole-induced polycystic ovary in rats via modulation of PPARα and TNFα/CD95 pathway.
Topics: Animals; Anti-Mullerian Hormone; Body Weight; Disease Models, Animal; Female; Fenofibrate; Humans; I | 2022 |
PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Fenofibrate; Fibric Acids; Gemfibrozil; Glucose | 2018 |
Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exe | 2013 |
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; H | 2013 |
Statins and fibrates do not affect development of spontaneous cartilage damage in STR/Ort mice.
Topics: Animals; Arthritis, Experimental; Biomarkers; Body Weight; Cartilage, Articular; Diet; Drug Evaluati | 2014 |
Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Blood | 2014 |
The peroxisomal proliferator-activated receptor (PPAR) α agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment.
Topics: Animals; Behavior, Animal; Body Weight; Cognition; Doublecortin Protein; Fenofibrate; Male; Motor Ac | 2014 |
Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Body Weight; Bone and Bones; Bone Densit | 2014 |
Ursodeoxycholic acid ameliorates fructose-induced metabolic syndrome in rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Fenofibrate; Fructose; Glutathione | 2014 |
Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Topics: Amino Acid Transport System ASC; Animals; Body Weight; Carnitine O-Palmitoyltransferase; Cholesterol | 2015 |
A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Blood Glucose; Body Weight; Cholesterol, Dietary; | 2015 |
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenof | 2015 |
Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; | 2016 |
Fenofibrate improves high-fat diet-induced and palmitate-induced endoplasmic reticulum stress and inflammation in skeletal muscle.
Topics: Animals; Body Weight; Cell Line; Diet, High-Fat; Endoplasmic Reticulum Stress; Female; Fenofibrate; | 2016 |
Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats.
Topics: Animals; Body Weight; Fenofibrate; Gene Expression Regulation; Glomerular Filtration Rate; Hypolipid | 2017 |
Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Eating; Fatty Acids, Nonesteri | 2008 |
Role of Nrf2 and oxidative stress on fenofibrate-induced hepatocarcinogenesis in rats.
Topics: Animals; Body Weight; Feeding Behavior; Fenofibrate; Gene Expression Profiling; Glutathione Peroxida | 2008 |
Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice.
Topics: Animals; Body Weight; Carcinogenicity Tests; Diethylnitrosamine; Disease Models, Animal; Fenofibrate | 2008 |
Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties.
Topics: 3-Hydroxybutyric Acid; Analysis of Variance; Animals; Body Weight; Diet, Ketogenic; Disease Models, | 2009 |
Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Topics: Abdominal Fat; Adiposity; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fenofibrate; H | 2009 |
Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Experimental; Diet; Fenofibr | 2009 |
Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice.
Topics: 3T3 Cells; Adipocytes; Animals; Blood Glucose; Body Weight; Cell Enlargement; Dietary Fats; Fenofibr | 2009 |
Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Eating | 2009 |
Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Carnitine O-Palmitoyltransferase | 2009 |
Adverse effect of fenofibrate on branched-chain alpha-ketoacid dehydrogenase complex in rat's liver.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); Amino Acids, Branched-Chain; Animals; Blotting, W | 2009 |
Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Topics: Adipose Tissue; Analysis of Variance; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Enzyme | 2009 |
Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy.
Topics: Animals; Arthritis, Experimental; Atrophy; Body Weight; Eating; Fenofibrate; Gene Expression; Hypoli | 2011 |
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood | 2010 |
Fenofibrate increases neuronal vasoconstrictor response in mesenteric arteries from diabetic rats: role of noradrenaline, neuronal nitric oxide and calcitonin gene-related peptide.
Topics: Animals; Body Weight; Calcitonin Gene-Related Peptide; Diabetes Mellitus; Electric Stimulation; Feno | 2011 |
Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.
Topics: Aging; Animals; Azo Compounds; Blood Pressure; Body Weight; Cholesterol; Disease Models, Animal; Ene | 2011 |
Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Catalase; Cytokines; Extremities; Fenofibrate; Glutat | 2012 |
The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat.
Topics: Animals; Blood Chemical Analysis; Body Weight; Dose-Response Relationship, Drug; Female; Fenofibrate | 2012 |
Influence of lipid imbalance on butyrylcholinesterase activity and biotransformation efficiency.
Topics: Adipose Tissue, White; Animals; Benzoylcholine; Biotransformation; Body Weight; Butyrylcholinesteras | 2012 |
Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetic Nephropathies; Dose-R | 2013 |
Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
Topics: Abdomen; Adipose Tissue; Animals; Body Weight; Carnitine O-Palmitoyltransferase; CD36 Antigens; Diab | 2002 |
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; | 2003 |
Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism.
Topics: Adipose Tissue; Animals; Body Composition; Body Weight; Diet; Dietary Fats; Female; Fenofibrate; Gen | 2002 |
Comparative effect of fenofibrate on hepatic desaturases in wild-type and peroxisome proliferator-activated receptor alpha-deficient mice.
Topics: Animals; Body Weight; Fatty Acid Desaturases; Fatty Acids; Fenofibrate; Liver; Male; Mice; Mice, Kno | 2002 |
Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice.
Topics: Adipose Tissue; Animals; Body Weight; Fenofibrate; Lipid Metabolism; Mice; Mice, Knockout; Obesity; | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; En | 2003 |
Trans-10,cis-12 CLA increases liver and decreases adipose tissue lipids in mice: possible roles of specific lipid metabolism genes.
Topics: Acyl-CoA Oxidase; Adiponectin; Adipose Tissue; Animals; Apolipoprotein A-I; Apolipoprotein C-III; Ap | 2003 |
Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Topics: Animals; Biomarkers; Blood Glucose; Body Weight; Catheterization; Cholesterol; Diabetes Mellitus, Ty | 2003 |
Profiling of hepatic gene expression in rats treated with fibric acid analogs.
Topics: Animals; Body Weight; Fenofibrate; Gene Expression Profiling; Liver; Male; Organ Size; Rats | 2004 |
Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice.
Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Apolipoproteins C; Body Weight; Cholesterol; Dietary Fats | 2004 |
Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Body Weight; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, | 2004 |
Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice.
Topics: Adipose Tissue; Animals; Body Composition; Body Weight; Dietary Fats; Eating; Fatty Acids; Female; F | 2004 |
Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol, HDL; Diet; Feno | 2005 |
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cho | 2005 |
Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice.
Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Cholesterol, | 2005 |
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Cytokines; Diabetes Mellitus, Type | 2005 |
The effects of fenofibrate on metabolic and vascular changes induced by chocolate-supplemented diet in the rat.
Topics: Animals; Body Weight; Cacao; Carbachol; Dietary Supplements; Dose-Response Relationship, Drug; Endot | 2005 |
PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Cells, Cultured; Collagen Type I; Diabetes Mellitu | 2006 |
Fenofibrate lowers lipid parameters in obese dogs.
Topics: Animals; Body Weight; Dog Diseases; Dogs; Dyslipidemias; Female; Fenofibrate; Hypolipidemic Agents; | 2006 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response | 2006 |
The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats.
Topics: Adipose Tissue; Animals; Body Temperature; Body Weight; Energy Metabolism; Fenofibrate; Hypolipidemi | 2007 |
Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen.
Topics: Adiposity; Animals; Body Weight; Cells, Cultured; DNA-Binding Proteins; Estradiol; Female; Fenofibra | 2007 |
Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
Topics: Acyl-CoA Oxidase; Animals; Body Weight; Carnitine O-Palmitoyltransferase; Diet; Fenofibrate; Gene Ex | 2008 |
Possible involvement of oxidative stress in fenofibrate-induced hepatocarcinogenesis in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Alkylating Agents; Animals; Body Weight; Carcinogens; Deoxyguanosine; D | 2008 |
Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, LDL; Eating; Fenofibrate; Hypercholesterolemia; Hypo | 2007 |
[Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
Topics: Animals; Body Weight; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Liver; Microbodies; Mic | 1980 |
Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster.
Topics: Animals; Body Weight; Cardiomyopathies; Cricetinae; Female; Fenofibrate; Heart; Hydroxymethylglutary | 1993 |
Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate.
Topics: Acyl-CoA Oxidase; Animals; Antioxidants; Body Weight; Catalase; Diet; Female; Fenofibrate; Glutathio | 1995 |
Altered hepatic metabolism of fatty acids in rats fed a hypolipidaemic drug, fenofibrate.
Topics: Acetoacetates; Animals; Body Weight; Cholesterol; Diet; Fatty Acids; Fenofibrate; Hypolipidemic Agen | 1996 |
Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
Topics: Acyl-CoA Oxidase; Animals; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins C; Body Weight; | 2000 |
Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
Topics: Amino Acid Sequence; Animals; Apolipoproteins; Base Sequence; Blood Glucose; Blotting, Western; Body | 2001 |
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen.
Topics: Adult; Aged; Apolipoproteins; Body Weight; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoprotei | 1979 |
Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice.
Topics: Animals; Body Weight; Clofibrate; Female; Fenofibrate; Fetus; Gestational Age; Hypolipidemic Agents; | 1989 |
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents.
Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-4 | 1987 |
Inductive effects of fenofibrate and metabolism of phenobarbital.
Topics: Animals; Body Weight; Cytochrome P-450 Enzyme System; Fenofibrate; In Vitro Techniques; Liver; Male; | 1988 |
Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
Topics: Adult; Apolipoproteins; Body Weight; Cholesterol; Cholesterol, HDL; Colestipol; Female; Fenofibrate; | 1986 |